Predictors and rate of asthma remission in a pediatric cohort: A Chiangrai Prachanukroh Hospital Study
Keywords:
Asthma remission, Predictive factors, Time to remissionAbstract
Background: Remission from asthma in children is the ultimate goal of treatment, with reports documented worldwide. Understanding remission rates and predictors can guide future management strategies.
Objectives: To determine the remission rate from asthma in pediatric patients and identify predictive factors for remission.
Methods: A retrospective review was conducted of medical records of patients aged 0–18 years diagnosed with asthma at Chiangrai Prachanukroh Hospital. Recovery rates were calculated using Cox regression analysis. Time to remission was estimated with Kaplan–Meier analysis, and predictive factors were identified using logistic regression.
Results: Of 296 patients (63% male), the mean age at symptom onset was 50 months, and mean age at diagnosis was 65 months. Remission occurred in 149 patients (50%), with an incidence of 8.27 per 100 person-years. Significant predictors included diagnosis before age 5 years, allergen avoidance, and use of inhaled corticosteroids at no more than moderate doses. Median time to remission was 108 months, 70 months, and 76 months for these respective factors.
Conclusions: Half of the pediatric asthma patients achieved remission. Early diagnosis, identification and avoidance of allergens, and milder disease requiring lower doses of inhaled corticosteroids were associated with higher remission rates. Allergen avoidance was the strongest predictor of earlier remission.
Downloads
References
Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145:757-65.
Vonk JM, Postma DS, Boezen HM, Grol MH, Schouten JP, Koëter GH, et al. Childhood factors associated with asthma remission after 30 years follow up. Thorax. 2004;59:925–9.
Wang AL, Datta S, Weiss ST, Tantisira KG. Remission of persistent childhood asthma: Early predictors of adult outcomes. J Allergy Clin Immunol. 2019;143:1752–9.
Heldin J, Malinovschi A, Johannessen A, Alving K , Holm M , Franklin KA , et al. Clinical remission of asthma and allergic rhinitis - in a longitudinal population study. J Asthma Allergy. 2022;15:1569–78.
Koefoed HJ, Vonk JM, Koppelman GH. Predicting the course of asthma from childhood until early adulthood. Curr Opin Allergy Clin Immunol. 2022;22:115–22.
Almqvist L, Rönmark E, Stridsman C, Backman H, Lindberg A, Lundbäck B, et al. Remission of adult-onset asthma is rare: A 15-year follow-up study. ERJ Open Res. 2020;6:00620-2020.
Tai A, Tran H, Roberts M, Clarke N, Gibon AM, Vidmar S, et al. Outcome of childhood asthma to the age of 50 years. J Allergy Clin Immunol. 2014;133:1572-8.
Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003;349:1414-22.
Jenkins MA, Hopper JL, Bowes G, Carlin JB, Flander LB, Giles GG. Factors in childhood as predictors of asthma in adult life. BMJ. 1994;309:90-3.
Burgess JA, Walters EH, Byrnes GB, Matheson MC, Jenkins MA, Wharton CY, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: A longitudinal study. J Allergy Clin Immunol. 2007;120:863-9.
Burgess JA, Matheson MC, Gurrin LC, Byrnes GB, Adams KS, Wharton CL, et al. Factors influencing asthma remission: A longitudinal study from childhood to middle age. Thorax. 2011;66:508-13.
Marco R, Locatelli F, Sunyer J, Burney P. Differences in incidence of reported asthma related to age in men and women: A retrospective analysis of the data of the European respiratory health survey. Am J Respir Crit Care Med. 2000;162:68-74.
Owens L, Laing IA, Zhang G, Le Souëf PN. Infant lung function predicts asthma persistence and remission. Respiratory. 2017;22:289-94.
Brzozowska A, Woicka‑Kolejwa K, Jerzynska J, Majak P, Stelmach I. Allergic rhinitis and house dust mite sensitization determine persistence of asthma in children. Indian J Pediatr. 2022;89:673–81.
Mailhot-Larouche S, Celis-Preciado C, Heaney LG, Couillard S. Identifying super-responders a review of the road to asthma remission. Ann Allergy Asthma Immumol. 2025;134:31-45.
Lanz MJ, Gilbert I, Szefler SJ, Murphy KR. Can early intervention in pediatric asthma improve long-term outcomes? a question that needs an answer. Pediatr Pulmonol. 2019;54:348–57.
Phelan PD, Robertson CF, Olinsky A. The Melbourne asthma study: 1964-1999. J Allergy Clin Immunol. 2002;109:189-94.
Hansen S, Baastrup SM, von Bülow A, Bjerrum AS, Schmid J, Rasmussen LM, et al. Clinical response and remission in patients with severe asthma treated with biologic therapies. Chest. 2024;165:253-66.
Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fagerås M, Cosio BG, et al. Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults. Am J Respir Crit Care Med. 2024;210:869–80.
Pavord I, Busse W, Israel E, Szefler S, Chen Z, Daizadeh N, et al. Dupilumab treatment leads to clinical asthma remission in patients with uncontrolled moderate-to-severe asthma with type2 inflammation. J Allergy Clin Immunol. 2021;147:AB4.
CastroM, Ambrose CS, Colice G, Roseti SL, Kmita K, Cook B, et al. On-treatment clinical remission with tezepelumab among patients with severe, uncontrolled asthma in the phase3 NAVIGATOR study. Eur Respir J. 2022;60:2287.
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, et al. Clinical remission in severe asthma: A pooled post-hoc analysis of the patient journey with Benralizumab. Adv Ther. 2022;39:2065-84.
Wechsler M, Brusselle G, Virchow J, Heaney L, Hunter G, Ponnarambil S, et al. M21 On-treatment clinical remission with Tezepelumab in patients with severe uncontrolled asthma in thephase3 DESTINATIONstudy. Thorax. 2023;78:A272–3.
Chen R, Dai Y, Yang D, Liu C, Han W, Gu W, et al. Clinical remission outcome in patients with severe asthma with an eosinophilic phenotype (SA-EP) receiving mepolizumab: A post-hoc analysis of aphase3, randomized, double-blinded placebo-controlled trial. J Allergy Clin Immunol. 2024;153:AB99.
Lugogo N, Oppenheimer J, Crawford J, Corbridge T, Howarth P, Igboekwe E, et al. Is asthma clinical remission achievable by inhaled therapy? a post-hoc analysis of single inhaler triple therapy with FF/UMEC/Vi in the CAPTAIN trial. J Allergy Clin Immunol. 2024;153:AB266.
Oppenheimer J, Pavord I, Crawford J, Corbridge T, Howarth P, Igboekwe E, et al. Influence of different thresholds for asthma control on clinical remission composite outcome in patients uncontrolled on ICS/LABA: A post hoc analysis of single inhaler triple therapy with FF/UMEC/VI in the CAPTAIN trial. What’s New Clin Asthma. Am J Respir Crit Care Med. 2024;C31.A5267-7.
Thomas D, McDonald VM, Stevens S, Baraket M, Hodge S, James A, et al. Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: A secondary analysis of a randomized, double-anonymized, placebo-controlled trial. Chest. 2024;166:262–70.
Farinha I, Heaney LG. Barriers to clinical remission in severe asthma. Respir Res. 2024;25:178.
Koefoed HJL, Vonk JM, Koppelman GH. Predicting the course of asthma from childhood until early adulthood. Curr Opin Allergy Clin Immunol. 2022;22:115–22.
To M, Tsuzuki R, Katsube O, Yamawaki S , Soeda S, Kono Y, et al. Persistent asthma from childhood to adulthood presents a distinct phenotype of adult asthma. J Allergy Clin Immunol Pract. 2020;8:1921-7.
Almqvist L, Ronmark E, Stridsman C, Backman H, Lindberg A, Lundback B, et al. Remission of adult-onset asthma is rare: A 15-year follow-up study. ERJ Open Res. 2020;6:00620–02020.
Tupper OD, Hakansson KEJ, Ulrik CS. Remission and changes in severity over 30 years in an adult asthma cohort. J Allergy Clin Immunol Pract. 2021;9:1595–603.
Westerhof GA, Coumou H, de Nijs SB, Weersink EJ, Bel EH. Clinical predictors of remission and persistence of adult-onset asthma. J Allergy Clin Immunol. 2018;141:104–9.
Tuomisto LE, Ilmarinen P, Niemela O, Haanpaa J, Kankaanranta T, Kankaanranta H. A 12-year prognosis of adult-onset asthma: Seinajoki adult asthma study. Respir Med. 2016;117:223–9.
Ronmark E, Lindberg A, Watson L, Lundback B. Outcome and severity of adult onset asthma—report from the obstructive lung disease in northern Sweden studies (OLIN). Respir Med. 2007;101:2370-7.
Carpaij OA, Burgess JK, Kerstjens HAM, Nawijn MC, vanden Berge M. A review on the pathophysiology of asthma remission. Pharmacol Ther. 2019;201:8–24.
Almqvist L, Andersson M, Backman H, Ronmark E, Hedman L. No remission in 60% of those with childhood-onset asthma-A population-based cohort followed from 8 to 28 years of age. Respir Med. 2024;224:107581.
นันทนา ศิริพิพัฒนมงคล. ผลกระทบของฝุ่นละอองขนาดเล็กกว่า 2.5 ไมครอนต่อเด็กโรคหืด. วารสารกุมารเวชศาสตร์. 2020;59:215-23.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The Royal College of Pediatricians Of Thailand
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
